NEW YORK - A New York federal judge overseeing the Pfizer Inc. securities multidistrict litigation on March 29 certified a class of shareholders who allege that their stock value was affected by misstatements and omissions concerning the safety of the pain drugs Celebrex and Bextra (In Re: Pfizer Inc. Securities Litigation, MDL Docket No. 1688, Nos. 04-cv-9866 and 05-md-1688, S.D. N.Y.; 2012 U.S. Dist. LEXIS 44330).